Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) Sees Large Increase in Short Interest

Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) saw a large growth in short interest during the month of July. As of July 15th, there was short interest totalling 59,900 shares, a growth of 215.3% from the June 30th total of 19,000 shares. Based on an average trading volume of 1,380,000 shares, the short-interest ratio is presently 0.0 days. Approximately 10.7% of the shares of the stock are sold short.

Salarius Pharmaceuticals Price Performance

Shares of NASDAQ:SLRX traded down $0.31 on Friday, reaching $3.19. 1,272,293 shares of the company traded hands, compared to its average volume of 861,955. The company’s 50 day moving average is $2.92 and its 200-day moving average is $3.90. The stock has a market capitalization of $1.91 million, a PE ratio of -0.15 and a beta of 0.92. Salarius Pharmaceuticals has a fifty-two week low of $1.35 and a fifty-two week high of $7.92.

Salarius Pharmaceuticals (NASDAQ:SLRX) last released its earnings results on Monday, May 13th. The company reported ($3.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($53.60) by $50.32. As a group, analysts expect that Salarius Pharmaceuticals will post -214.4 EPS for the current year.

Salarius Pharmaceuticals Company Profile

Salarius Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma.